The role of visceral hypersensitivity in the pathogenesis of irritable bowel syndrome

Makarova, A A; Александровна, Макарова Алина; Ручкина, И Н; Николаевна, Ручкина Ирина; Парфенов, А И; Иванович, Парфенов Асфольд; Indeykina, L.Kh.; Лилия, Хасанбековна Индейкина; Romashkina, Natalia V.; Витальевна, Ромашкина Наталия

doi:10.26442/00403660.2021.08.200916

Terapevticheskii arkhiv

2021

DOI: 10.26442/00403660.2021.08.200916

|View full text |Cite

The role of visceral hypersensitivity in the pathogenesis of irritable bowel syndrome

A A Makarova

Макарова Алина Александровна²,

И Н Ручкина

et al.

Abstract: This research includes visceral sensitivity and its mechanisms involved in the development of irritable bowel syndrome. Visceral hypersensitivity occupies the key place. The research has the description of etiological factors that form visceral hypersensitivity and also visceral sensitivity instrumental research methods, based on the use of the balloon dilation. The research also has the schemes of drug therapy for irritable bowel syndrome meanwhile the special attention is paid to the possible use of the sorb… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Drug therapy’s new options in the treatment of the severe irritable bowel syndrome

Makarova,

Ruchkina,

Diukova

et al. 2023

Terapevticheskii arkhiv

Self Cite

View full text Add to dashboard Cite

Background. Stress, individual characteristics of each patient, visceral hypersensitivity and intestinal motility have the key importance in the pathogenesis of irritable bowel syndrome (IBS). In recent years, there has been growing interest in the use of selective serotonin and norepinephrine reuptake inhibitors (SNRIs) in the complex therapy of IBS patients with somatoform disorders. Aim. To examine the effectiveness of the SNRIs antidepressant therapy in the treatment of patients with IBS and diarrhea (IBS-D) with extraintestinal manifestations. Materials and methods. 42 patients with severe IBS and diarrhea (IBS-D) were examined, among them 22 female with a median age of 32 years old (22; 38), and 20 male with a median age of 31 years old (25; 35). Treatment with duloxetine 60 mg/day was prescribed. The effectiveness of the therapy was assessed after eight weeks. The IBS clinical symptoms dynamics were assessed by the intensity of pain syndrome and bloating, which were determined using Visual Analogue Pain Scale (VAS), stool frequency and shape based on the Bristol stool scale; Visceral sensitivity threshold was assessed according to the Balloon dilatation test. There was studied the effect of the duloxetine on the extraintestinal manifestations of IBS. The psycho-emotional state was assessed using the Beck scale of anxiety and depression and the SpielbergerKhanin scale by psychiatrist, neurologist-vegetol. Results. All patients showed positive dynamics after eight weeks duloxetine treatment: the decrease of pain syndrome from 9 (9; 10) to 2 (2; 3) points, bloating from 8 (8; 9) points to 2,5 (1; 3) points according to VAS, and defecation frequency from 10 (9; 12) to 2 (1; 2) times a day; the change of stool consistency from 6th (6; 7) to 3rd (3; 4) type. The visceral sensitivity threshold increased: the time of appearance of the first urge to defecate increased from 56 (34; 74) ml to 95 (80; 98) ml. Significantly decreased extraintestinal manifestations of IBS. In reassessing each patients individual characteristics there were the decrease of the depression level according to the Beck scale from 26 (23; 32) to 11.5 (10; 13) points and personal personal anxiety level according to the SpielbergerKhanin scale from 42.5 (35; 53) to 22 (20; 24) points, as well as the decrease of situational anxiety from 40 (37; 49) to 22 (21; 36) points. Conclusion. The severe course of IBS-D is mainly associated with the patients individual characteristics and anxiety or anxiety-depressive syndromes. The positive impact of duloxetine therapy in severe IBS-D with extraintestinal manifestations is associated with the regulation of serotonergic and noradrenergic activity of the central.

show abstract

Drug therapy’s new options in the treatment of the severe irritable bowel syndrome

Makarova,

Ruchkina,

Diukova

et al. 2023

Terapevticheskii arkhiv

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The role of visceral hypersensitivity in the pathogenesis of irritable bowel syndrome

Cited by 1 publication

References 26 publications

Drug therapy’s new options in the treatment of the severe irritable bowel syndrome

Drug therapy’s new options in the treatment of the severe irritable bowel syndrome

Contact Info

Product

Resources

About